Lombard Medical Technologies (LSE:LMT) Momentum Rank : 0 (As of Jun. 06, 2024)

View and export this data going back to . Start your Free Trial

What is Lombard Medical Technologies Momentum Rank?

Lombard Medical Technologies has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Lombard Medical Technologies Momentum Rank Related Terms

Thank you for viewing the detailed overview of Lombard Medical Technologies's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lombard Medical Technologies (LSE:LMT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lombard Medical Technologies PLC (LSE:LMT) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.lombardmedical.com

Lombard Medical Technologies PLC is engaged in the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through the group's own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. The principal product, the AorfixT AAA stent graft has European CE mark approval for use in patients with high-angle-neck aneurysms of up to 90 degrees. The group has operations in United Kingdom and United States of America.